ERBB2 and breast carcinoma: CD16+Vγ9Vδ2 T cells can recognize monoclonal antibody coated lymphoma, chronic lymphocytic leukemia (CLL) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells and exert anti-tumor effect via ADCC [80].